ATE435660T1 - Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen - Google Patents

Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen

Info

Publication number: ATE435660T1
Authority: AT; Austria
Prior art keywords: tumor antigens; polypeptide consisting; immunogenic polypeptide; polypeptide; optimized
Prior art date: 2005-12-23

Application number

AT05850393T

Other languages

English (en)

Inventor

Konstantinos Kosmatopoulos

Sebastien Cornet

Original Assignee

Vaxon Biotech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-23

Filing date

2005-12-23

Publication date

2009-07-15

2005-12-23 Application filed by Vaxon Biotech filed Critical Vaxon Biotech

2009-07-15 Application granted granted Critical

2009-07-15 Publication of ATE435660T1 publication Critical patent/ATE435660T1/de

Links

102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
229920001184 polypeptide Polymers 0.000 title abstract 4
206010028980 Neoplasm Diseases 0.000 title abstract 2
239000000427 antigen Substances 0.000 title 1
102000036639 antigens Human genes 0.000 title 1
108091007433 antigens Proteins 0.000 title 1
230000002163 immunogen Effects 0.000 title 1
229940022399 cancer vaccine Drugs 0.000 abstract 2
102000039446 nucleic acids Human genes 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 2
150000007523 nucleic acids Chemical class 0.000 abstract 2
150000001413 amino acids Chemical group 0.000 abstract 1
210000004443 dendritic cell Anatomy 0.000 abstract 1
230000005847 immunogenicity Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT05850393T 2005-12-23 2005-12-23 Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen ATE435660T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP2005/014212 WO2007073768A1 (en)	2005-12-23	2005-12-23	Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof

Publications (1)

Publication Number	Publication Date
ATE435660T1 true ATE435660T1 (de)	2009-07-15

Family

ID=36000393

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05850393T ATE435660T1 (de)	2005-12-23	2005-12-23	Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen

Country Status (12)

Country	Link
US (1)	US7973128B2 (de)
EP (1)	EP1962889B1 (de)
JP (1)	JP4929290B2 (de)
CN (1)	CN101370513B (de)
AT (1)	ATE435660T1 (de)
CA (1)	CA2634480C (de)
DE (1)	DE602005015368D1 (de)
DK (1)	DK1962889T3 (de)
ES (1)	ES2330658T3 (de)
PL (1)	PL1962889T3 (de)
PT (1)	PT1962889E (de)
WO (1)	WO2007073768A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010115229A1 (en) *	2009-04-09	2010-10-14	The University Of Melbourne	Immunogenic composition and uses thereof
CN102153658A (zh) *	2011-01-19	2011-08-17	上海科医联创生物科技有限公司	肿瘤抗原、dc肿瘤疫苗及其制备方法
EP2886127A1 (de)	2013-12-18	2015-06-24	Vaxon Biotech	Verfahren zur Emulgierung eines Triepitoppeptids mit Montanid und Kits zu seiner Durchführung
EP2977059A1 (de) *	2014-07-22	2016-01-27	Vaxon Biotech	Immunogenes Polypeptid aus HLA-B7-beschränkten, tumorantigenabgeleiteten, optimierten kryptischen Peptiden und Verwendungen davon
CN104926944B (zh) *	2015-05-22	2018-04-13	北京康爱瑞浩生物科技股份有限公司空港分公司	多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途
US11058751B1 (en)	2020-11-20	2021-07-13	Think Therapeutics, Inc.	Compositions for optimized RAS peptide vaccines
CN116710115A (zh)	2020-11-20	2023-09-05	思维疗法股份有限公司	用于优化的肽疫苗的组合物和方法
US11421015B2 (en)	2020-12-07	2022-08-23	Think Therapeutics, Inc.	Method of compact peptide vaccines using residue optimization
US11464842B1 (en)	2021-04-28	2022-10-11	Think Therapeutics, Inc.	Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1568373A3 (de)	1999-12-10	2005-12-21	Epimmune Inc.	Induzierung von zellulärer Immunantwort auf HER2/neu mit Hilfe von Peptid- und Nukleinsäurezubereitungen
US7851212B2 (en) *	2000-05-10	2010-12-14	Sanofi Pasteur Limited	Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
FR2812087B1 (fr) *	2000-07-21	2007-05-11	Inst Nat Sante Rech Med	Procede de criblage de peptides utilisables en immunotherapie

2005
- 2005-12-23 US US12/158,736 patent/US7973128B2/en active Active
- 2005-12-23 DE DE602005015368T patent/DE602005015368D1/de not_active Expired - Lifetime
- 2005-12-23 JP JP2008546143A patent/JP4929290B2/ja not_active Expired - Lifetime
- 2005-12-23 ES ES05850393T patent/ES2330658T3/es not_active Expired - Lifetime
- 2005-12-23 CA CA2634480A patent/CA2634480C/en not_active Expired - Lifetime
- 2005-12-23 AT AT05850393T patent/ATE435660T1/de active
- 2005-12-23 PL PL05850393T patent/PL1962889T3/pl unknown
- 2005-12-23 DK DK05850393T patent/DK1962889T3/da active
- 2005-12-23 PT PT05850393T patent/PT1962889E/pt unknown
- 2005-12-23 CN CN2005800525070A patent/CN101370513B/zh not_active Expired - Lifetime
- 2005-12-23 EP EP05850393A patent/EP1962889B1/de not_active Expired - Lifetime
- 2005-12-23 WO PCT/EP2005/014212 patent/WO2007073768A1/en not_active Ceased

Also Published As

Publication number	Publication date
US20090130133A1 (en)	2009-05-21
WO2007073768A1 (en)	2007-07-05
PT1962889E (pt)	2009-10-14
DK1962889T3 (da)	2009-11-02
JP4929290B2 (ja)	2012-05-09
EP1962889A1 (de)	2008-09-03
ES2330658T3 (es)	2009-12-14
EP1962889B1 (de)	2009-07-08
JP2009520472A (ja)	2009-05-28
CA2634480A1 (en)	2007-07-05
DE602005015368D1 (de)	2009-08-20
PL1962889T3 (pl)	2010-03-31
CN101370513B (zh)	2013-04-03
US7973128B2 (en)	2011-07-05
CN101370513A (zh)	2009-02-18
CA2634480C (en)	2013-10-15

Similar Documents

Publication	Publication Date	Title
PT2121731E (pt)	2013-10-24	Vacinas peptídicas para cancros que expressam antigénios associados a tumores
JP2012501959A5 (de)	2012-10-11
JP2014507146A5 (de)	2014-06-19
DK1922335T3 (da)	2010-04-19	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
MX358725B (es)	2018-09-03	Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
EP2562183A8 (de)	2013-05-08	Neuartige immunogenetische Epitope zur Immuntherapie
MXPA02006888A (es)	2004-08-12	Flavivirus recombinantes y metodos para utilizar los mismos.
NZ598605A (en)	2014-04-30	Vaccine against african horse sickness virus
CA2408328A1 (en)	2001-11-15	Immunogenic polypeptides encoded by mage minigenes and uses thereof
JP2007516696A5 (de)	2012-04-05
WO2005007673A3 (en)	2007-11-22	Immunogenic peptides
US20190321458A1 (en)	2019-10-24	Formulation for administration of rna
MX2009007261A (es)	2009-11-11	Vacuna de peptido foxp3.
CY1112867T1 (el)	2016-04-13	Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
DE602005015368D1 (de)	2009-08-20	Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen
NZ594268A (en)	2013-05-31	Grass peptides for vaccine
PH12018502430A1 (en)	2019-03-18	Vaccines
TW201008576A (en)	2010-03-01	New fusion proteins and their use for the preparation of vaccines against hepatitis C
MX2010010025A (es)	2011-09-01	Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones.
WO2005076975A3 (en)	2005-11-10	Complexed polypeptide and adjuvant for improved vaccines
AR053372A1 (es)	2007-05-02	Proteinas inmunologicas de lawsonia intracellularis
UA102274C2 (ru)	2013-06-25	Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
RU2021112253A (ru)	2023-01-20	Вирусоподобные частицы cmv, модифицированные путем слияния
WO2009149094A3 (en)	2010-03-04	Cytotoxic t cell defined egfr peptide and an optimized derivative peptide
CY1114720T1 (el)	2016-10-05	Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια

Legal Events

Date

Code

Title

Description

2010-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1962889

Country of ref document: EP